Lion, L.; Epidémiologie et Economie de la santé, Liège Université, Belgium, Mme Laurine Lion, CHU Liège, Liège, 4000, Belgium
LECLERCQ, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
Plomteux, O.; Service de Gastroentérologie, CHC Saint-Joseph, Belgium
Bours, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique humaine
Language :
French
Title :
Etude des risques oncologiques associés au syndrome de Lynch en région liégeoise
Alternative titles :
[en] Study of cancer risks associated with Lynch syndrome in the Liège region
Lynch HT, Snyder CL, Shaw TG et al.- Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer, 2015, 15, 181-194.
Peltomäki P.- Role of DNA mismatch repair defects in the pathogenisis of human cancer. J Clin Oncol, 2003, 21, 1174-1179.
Berends MJ, Wu Y, Sijmons RH, et al.- Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Med Genet, 2002, 70, 26-37.
Miyaki M, Konishi M, Tanaka K, et al.- Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet, 1997, 17, 271-272.
Senter L, Clendenning, M, Sotamaa, K, et al.- The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. Gastroenterology, 2008, 135, 419-428.
Kuiper RP, Vissers LE, Venkatachalam R, et al.-Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat, 2011, 32, 407-414.
Aarnio M, Sankila R, Pukkala E, et al.- Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer, 1999, 81, 214-218.
Giardiello FM, Allen JI, Axilbund JE, et al.- Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology, 2014, 147, 502-526.
Hampel H, Stephens JA, Pukkala E, et al.- Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology, 2005, 129, 415-421.
Barrow E, Hill J, Evans G.- Cancer risk in Lynch syndrome. Fam Cancer, 2013, 12, 229-240.
Dunlop MG, Farrington SM, Carothers AD, et al.- Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet, 1997, 6, 105-110.
Baglietto L, Lindor NM, Dowty JG, et al.- Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst, 2010, 102, 193-201.
Senter L, Clendenning M, Sotamaa K, et al.- The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. Gastroenterology, 2008, 135, 419-428.
Kempers MJ, Kuiper RP, Ockeloen CW, et al.- Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol, 2011, 12, 49-55.
Barrow E, Robinson L, Alduaij W, et al.- Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet, 2009, 75, 141-149.
Alarcon F, Lasset C, Carayol J, et al.- Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet, 2007, 15, 831-836.
Bonadona V, Bonaïti B, Olschwang S, et al.-Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome. JAMA, 2011, 305, 2304-2310.
van der Post RS, Kiemeny LA, Ligtenberg MJ, et al.- Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet, 2010, 47, 464-470.
Vasen HF, Wijnen JT, Menko FH, et al.- Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology, 1996, 110, 1020-1027.
Hendriks YM, Wagner A, Morreau H, et al.- Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counselling and surveillance. Gastroenterology, 2004, 127, 17-25.
Tafe LJ, Riggs ER & Tsongalis GJ.- Lynch syndrome presenting as endometrial cancer. Clin Chem, 2014, 60, 111-121.
National Cancer Institute. (2015). Age and cancer risk. En ligne: https://www.cancer.gov/about-cancer/causes-prevention/risk/age consulté le 14 avril 2017.
Schneider R, Schneider C, Jakobeit C, et al.-Gender-specific aspects of Lynch Syndrome and Familial Adenomatous Polyposis. Viszeralmedizin, 2014, 30, 82-88.
Manchanda R, Saridogan E, Abdelraheim A, et al.- Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch Syndrome (LS). Arch Ggynecol Obstet, 2012, 286, 1555-1562.
Lynch HT, Lynch PM, Lanspa SJ, et al.- Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin Genet, 2009, 76, 1-18.
Vasen HF, Blanco I, Aktan-Collan K, et al.-Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.
Aarnio M, Säily M, Juhola M. et al.- Uroepithelial and kidney carcinoma in Lynch Syndrome. Fam Cancer, 2012, 11, 395-401.
Kohlmann W, Gruber SB. (2014). Lynch Syndrome. En ligne: https://www.ncbi.nlm.nih.gov/books/ NBK1211 consulté le 15 janvier 2016.
Aarnio M. (2012). Clinicopathological features and management of cancers in lynch syndrome. En ligne: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350853/pdf/PRI2012-350309.pdf consulté le 12 avril 2017.
